Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05768945 · ClinicalTrials.gov registry record
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 742,670
- Enrollment target
NCT05768945: Completed study, sponsored by Brigham and Women's Hospital.
NCT05768945 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 742,670 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05768945 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 742,670 participants
- Enrollment target
Study Summary
This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.
Primary Outcome
Time to dementia onset, i.e., Alzheimer's disease, vascular dementia, senile, presenile, or unspecified dementia, or dementia in other diseases classified elsewhere. Please refer to uploaded protocol for full definition due to size limitations.
Interventions
- DRUG Semaglutide
- DRUG DPP-4 inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 742,670 participants |
| Start Date | 2022-11-30 |
| Est. Completion | 2023-12-31 |
What the finished NCT05768945 record still lists
NCT05768945 is an observational study that tracks outcomes without assigning an intervention. Its 742,670 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Semaglutide is the first listed.
NCT05768945 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05768945 about?
NCT05768945 is a clinical study titled "Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors". This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.
What is the current status of trial NCT05768945?
This trial is currently completed. The enrollment target is 742,670 participants. The study started on 2022-11-30. Estimated completion is 2023-12-31.
What interventions are being tested in trial NCT05768945?
The interventions under investigation include: Semaglutide (DRUG), DPP-4 inhibitor (DRUG).
Who is sponsoring clinical trial NCT05768945?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01073475 · 950,000 participants
Maternal Newborn Health Registry
- NCT06029933 · 960,000 participants
Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years
- NCT05065060 · 500,000 participants
Parkinson Progression Marker Initiative Online (PPMI Online)
- NCT06017687 · 500,000 participants · NA
Data Collection and Evaluation of OptiBP Under Investigational Use
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI